Roundtable Program
Q3 IR Panel – One Size Doesn’t Fit All: IR Across Market Caps
Not all IR functions look the same, but the stakes are consistently high. Like strategic communications, the goals, strategies, and scale of IR programs depend on a company’s market cap, development stage, and geographic reach. Recognizing these differences is critical when aligning IR with broader communications and corporate affairs priorities.
In this one-hour virtual panel, hear from deeply experienced IR leaders representing the small-cap, mid-cap, and large-cap perspectives. Speakers Susie Lisa of Vertex and Jen Harsey Robinson, most recently at Verve, both blend Wall Street and in-house expertise to lead companies through significant value-creating milestones and everything in between.
Why Watch
- Gain perspective on how IR priorities shift across market caps and stages
- Explore where IR and communications intersect, and how to navigate shared ownership of critical moments
- Hear how senior IR leaders approach milestone communications and ongoing market engagement, and what that means for communicators partnering with them
Featuring
- Susie Lisa, Senior Vice President, Investor Relations, Vertex Pharmaceuticals
- Jennifer Harsey Robinson, most recently Senior Vice President, Investor Relations and Corporate Communications, Verve Therapeutics (acquired by Lilly)
Panel moderator
- David Connolly, T2B IR Roundtable Member and Head of Investor Relations and Corporate Communications, Rhythm Pharmaceuticals